Three cases of immune-related hypopituitarism after atezolizumab–bevacizumab treatment for hepatocellular carcinoma-Reference-Cited by-同舟云学术

Three cases of immune-related hypopituitarism after atezolizumab–bevacizumab treatment for hepatocellular carcinoma

Published:2023-02-23 Issue:3 Volume:16 Page:422-431
ISSN:1865-7257
Container-title:Clinical Journal of Gastroenterology
language:en
Short-container-title:Clin J Gastroenterol

Author:

Furuichi Nozomi,Naganuma Atsushi,Kaburagi Takuya,Suzuki Yuhei,Hoshino Takashi,Shibusawa Nobuyuki,Horiguchi Suguru,Hatanaka Takeshi,Kakizaki Satoru^ORCID,Uraoka Toshio

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12328-023-01775-0.pdf

Reference31 articles.

1. Fujiwara N, Friedman SL, Goossens N, et al. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol. 2018;68:526–49.

2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–14.

3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.

4. Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update. Oncology. 2014;87:22–31.

5. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Isolated hypoprolactinemia: The rarest of the rare?;Reviews in Endocrine and Metabolic Disorders;2024-09-13

2. Cortisol: Biosensing and detection strategies;Clinica Chimica Acta;2024-08

4. Review of Peripheral Blood Eosinophilia: Workup and Differential Diagnosis;Hemato;2024-03-16

5. Systemic therapies in hepatocellular carcinoma: A revolution?;United European Gastroenterology Journal;2024-01-24